Geometry.Net - Health_Conditions: Respiratory Syncytial Virus

AAP Policy Statement - Prevention Of Respiratory Syncytial Virus Infections: Ind
Prevention of respiratory syncytial virus Infections Indications forthe Use of Palivizumab and Update on the Use of RSVIGIV (RE9839).
http://www.aap.org/policy/re9839.html

Extractions: Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIV (RE9839) AMERICAN ACADEMY OF PEDIATRICS Committee on Infectious Diseases and Committee on Fetus and Newborn Most of the guidelines from the American Academy of Pediatrics for the selection of infants and children to receive RSV-prophylaxis remain unchanged. Palivizumab has been shown to provide benefit for infants who were 32 to 35 weeks of gestation at birth. RSV-IGIV is contraindicated and palivizumab is not recommended for children with cyanotic congenital heart disease. The number of patients with adverse events judged to be related to palivizumab was similar to that of the placebo group (11% vs 10%, respectively); discontinuation of injections for adverse events related to palivizumab was rare. ABBREVIATIONS. RSV, respiratory syncytial virus; CLD, chronic lung disease; FDA, Food and Drug Administration; CHD, congenital heartdisease; RSV-IGIV, respiratory syncytial virus immune globulin intravenous; AAP, American Academy of Pediatrics; ICU, intensive care unit; MMR, measles-mumps-rubella; IPV, inactivated poliovirus vaccine; OPV, oral poliovirus vaccine; IGIV, immune globulin intravenous. Prophylaxis to prevent respiratory syncytial virus (RSV) infection in infants and children at increased risk for severe disease, particularly those with chronic lung disease (CLD) receiving medical management on a long-term basis, is now available using either an intravenous or an intramuscular preparation. Choosing which product to use in individual patients will depend on age, availability of intravenous access, cost, and other factors. Neither preparation is approved by the Food and Drug Administration (FDA) for infants or children with congenital heart disease (CHD). Unlike respiratory syncytial virus immune globulin intravenous (RSV-IGIV), recipients of palivizumab do not require delaying measles-containing vaccine or varicella vaccine.
Policy Statement
respiratory syncytial virus Immune Globulin Intravenous Indications for Use (RE9718). Controlof nosocomial respiratory syncytial virus infections. Pediatrics.
http://www.aap.org/policy/re9718.html

Extractions: Pediatrics Volume 99, Number 4 April 1997, p 645-650 Committee on Infectious Diseases, Committee on Fetus and Newborn CLINICAL STUDIES RSV-IGIV Clinical Efficacy Table 1 Results from a multi-institution, randomized, albumin placebo-controlled trial (the PREVENT study) in 510 infants younger than 24 months with BPD and/or prematurity are shown in Table 2 .[2] Ninety-five percent of children completed the protocol, and 85% completed four or five infusions. Monthly RSV-IGIV infusions reduced RSV-associated illness frequency and severity by 40% to 60%. Subgroup analysis did not demonstrate evidence of interactions between treatment and age of the patient or underlying disease category. The RSV-IGIV-associated reduction in hospitalization rate was greater for infants and children with BPD than those with prematurity only (49% vs 20%, respectively; Table 2 ). Moderate to severe adverse events were not more frequent in patients receiving RSV-IGIV than in control patients and consisted of fever, increased respiratory distress, and rash. These adverse events were easily managed medically and did not occur with subsequent infusions. Of additional interest was an RSV-IGIV-associated reduction in: (1) non-RSV respiratory hospitalization, a 50% lower rate ( P = .002) and 42% fewer hospital days (
Ribavirin For Respiratory Syncytial Virus Infection Of The Lower Respiratory Tra
Click here to order the full review. Ribavirin for respiratory syncytial virus infectionof the lower respiratory tract (Cochrane Review). Randolph AG, Wang EEL.
http://www.cochrane.org/cochrane/revabstr/ab000181.htm

Extractions: Abstract from The Cochrane Library , Issue 1, 2003 Click here to order the full review Randolph AG, Wang EEL ABSTRACT A substantive amendment to this systematic review was last made on 11 January 2000. Cochrane reviews are regularly checked and updated if necessary. Background: Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract infection in infants leading to 100,000 hospitalizations annually. Ribavirin is approved for treatment of these infections, but its use is controversial because of questions on its efficacy, concerns about occupational exposure and its high cost. Objectives: Respiratory syncytial virus (RSV) is a common cause of pneumonia in infants. Ribavirin is the only antiviral therapy available against RSV. The objective of this review was to assess the effects of aerosolized ribavirin for infants with RSV lower respiratory tract infection. Search strategy: We searched MEDLINE from 1975 to 1999, we scanned reference lists of articles, and we contacted experts in the field.
Immunoglobulin For Preventing Respiratory Syncytial Virus Infection (Cochrane Re
Click here to order the full review. Immunoglobulin for preventing respiratorysyncytial virus infection (Cochrane Review). Wang EEL, Tang NK. ABSTRACT
http://www.cochrane.org/cochrane/revabstr/ab001725.htm

Extractions: Abstract from The Cochrane Library , Issue 1, 2003 Click here to order the full review Wang EEL, Tang NK ABSTRACT A substantive amendment to this systematic review was last made on 10 March 1999. Cochrane reviews are regularly checked and updated if necessary. Background: Respiratory Syncytial virus, the most important cause of lower respiratory tract infections in infants and young children in industrialized countries, is associated with increased morbidity in premature infants with or without bronchopulmonary dysplasia as well as those with congenital heart disease. Because of observations that lower rates of disease occur immediately after birth, presumably due to vertical transmission of maternal antibody, and animal studies where protection from pneumonia was observed through administration of immune globulin, the efficacy of passive prophylaxis in premature infants has been studied. Objectives: This meta-analysis was performed to assess the effects of polyclonal respiratory syncytial virus hyperimmune globulin or monoclonal antibody in preventing RSV hospitalization, receipt of intensive care, mechanical ventilation, and mortality in those with underlying prematurity, bronchopulmonary dysplasia, or congenital heart disease. Search strategy: We searched the Cochrane Acute Respiratory Infections trials register and MEDLINE in March, 1999. In addition, abstracts on these topics were sought from the Pediatric Academies Meetings and the Intersciences Conference on Antimicrobial Agents and Chemotherapy for the years 1994 to 1997, inclusive.
Research & Development - Respiratory Syncytial Virus (RSV)
respiratory syncytial virus (RSV) is the single most important cause of severelower respiratory tract infections in infants and young children.
http://www.boehringer-ingelheim.ca/research/res_area_rsv.asp

Extractions: Respiratory Syncytial Virus (RSV) is the single most important cause of severe lower respiratory tract infections in infants and young children. RSV (an RNA virus) is highly contagious and is spread through contact with contaminated nasal secretions. Like Influenza virus, RSV infections occur in epidemics typically during winter to early spring.
Respiratory Syncytial Virus (RSV) Or Bronchiolitis (0-12 Months)
Baby Health respiratory syncytial virus (RSV) or bronchiolitis Approvedby the BabyCenter Medical Advisory Board What's below My
http://www.babycenter.com/refcap/baby/babyills/1754.html

Extractions: The most severe cases of RSV are in babies under 6 months old because their lungs aren't fully developed yet and the damage from these infections can linger. Premature babies, twins and other multiples, and babies born with respiratory problems or congenital heart disease are at particularly high risk for contracting a serious infection. Research suggests that babies infected with RSV are more likely to develop asthma and other respiratory problems later in life.
Respiratory Syncytial Virus (RSV) (12-36 Months)
Toddler Health respiratory syncytial virus (RSV) or bronchiolitisApproved by the BabyCenter Medical Advisory Board What's below
http://www.babycenter.com/refcap/toddler/toddlerills/11385.html

Extractions: Respiratory syncytial virus (RSV) infects all children sooner or later, and it is rarely more troublesome for a toddler than the common cold. RSV poses the biggest threat to babies between the ages of 2 and 7 months because it can cause bronchiolitis (a disease in which the smallest airways of the lungs swell and fill with mucus, blocking airflow) and pneumonia (an inflammation of the lungs). To find out more about RSV in babies, click here . The biggest problem with RSV for toddlers is that it can also lead to ear infections
Respiratory Syncytial Virus - Material Safety Data Sheets (MSDS)
MATERIAL SAFETY DATA SHEET INFECTIOUS SUBSTANCES. SECTION I - INFECTIOUS AGENT.NAME respiratory syncytial virus. SYNONYM OR CROSS REFERENCE RSV, Pneumovirus.
http://www.hc-sc.gc.ca/pphb-dgspsp/msds-ftss/msds125e.html

Extractions: Material Safety Data Sheets - Index MATERIAL SAFETY DATA SHEET - INFECTIOUS SUBSTANCES SECTION I - INFECTIOUS AGENT NAME: Respiratory syncytial virus SYNONYM OR CROSS REFERENCE: RSV, Pneumovirus CHARACTERISTICS: Paramxyoviridae; pleomorphic, 150-300 nm diameter; enveloped virions; single stranded linear RNA; non-segmented negative sense genome; lack hemagglutinin and neuraminidase activities SECTION II - HEALTH HAZARD PATHOGENICITY: Most common cause of common cold-like lower respiratory tract illness in infants and young children; causes common colds in adults, febrile bronchitis in infants and older children, pneumonia in infants, and bronchiolitis in very young babies; reinfection common and results in mild upper respiratory infection; can cause severe illness in the elderly and immunocompromised EPIDEMIOLOGY: HOST RANGE: Humans INFECTIOUS DOSE: MODE OF TRANSMISSION: Respiratory secretions; inhalation of large droplets ; fomites; direct oral contact; indirectly by hands, handkerchiefs and eating utensils or other articles freshly soiled by respiratory discharges INCUBATION PERIOD: 4 to 5 days COMMUNICABILITY: Viral shedding may persist for several weeks after symptoms subside SECTION III - DISSEMINATION RESERVOIR: Humans ZOONOSIS: None VECTORS: None SECTION IV - VIABILITY DRUG SUSCEPTIBILITY: Ribavirin is clinically beneficial when delivered as a small aerosol spray SUSCEPTIBILITY TO DISINFECTANTS: Susceptible to many disinfectants; 1% sodium hypochlorite, 70% ethanol, 2% glutaraldehyde, detergents
Respiratory Syncytial Virus
respiratory syncytial virus. Diseases Sites and Sources DiagnosticFactors Virulence Factors Treatment and Prevention Commentary
http://www.medinfo.ufl.edu/year2/mmid/bms5300/bugs/respsync.html

Extractions: Croup harsh cough barking cough hoarseness dyspnea swelling laryngeal obstruction respiratory droplets, source day-care centers, source hands, source infants, pathogen respiratory tract, pathogen LRT, pathogen URT, pathogen serology antigen detection immunoflourescence of resp. epithelium viral antigen virus isolation glycoprotein cell fusion cytolysis isolation humidifier ribivarin ribivarin, aerosolized human immune globulin respigam http://www.respigam.medimmune.com/ Updated: May 12, 1999 MMID Home Page Bugs Index Cases Index
Respiratory Syncytial Virus
respiratory syncytial virus. Author Timothy Paustian, Posted 9/11/00; 20606PM. Topic respiratory syncytial virus. Msg 45 (top msg in thread).
http://www.bact.wisc.edu:81/ScienceEd/discuss/msgReader$45

Extractions: by Lindsey Monk Sunday, August 6, 2000 Respiratory Syncytial Virus (RSV) is one of the most common viruses, yet most people who have been affected by the virus never realize they are ill. However, this particular virus can cause severe lower respiratory illnesses such as bronchiolitis and pneumonia in infants, young children and the elderly. This virus can also have serious physiological effects on distinct groups our population, especially children who were born premature or who have immunodeficiency's, chronic lung conditions or congenital heart disease. This particular virus is very dangerous to young children because of their undeveloped immune system. However, it is known that two types of RSV, Type A and Type B, exist. Type B causes a mild upper respiratory infection that affects almost everybody and Type A is a severe lower respiratory tract infection that mainly affects infants, the elderly and those with a compromised immune system. Pathophysiologically, RSV attacks the bronchoalveolar epithelium, causing epithelial cell necrosis and an inflammatory response with a peri-bronchiolar infiltrate of lymphocytes, plasma cells and macrophages (Miller et al.,1999). The feeble or those with weak or compromised immunes systems are susceptible to the most severe form of RSV. Infants and children are at high risk for lower respiratory tract infections caused by the Type A virus. According to Miller et al. (1999), RSV is responsible for 45% to 75% of all cases of bronchiolities and pneumonia in infants and young children. During a child's first RSV infection, between 25% and 40% of infants and young children have signs or symptoms of bronchiolitis or pneumonia (National Center for Infectious Disease). RSV also tends to occur between six-weeks and two years of life. The severe Type A virus tends to occur in very young children who have a history of prematurity, congenital heart disease, chronic lung conditions or immunodeficiency. Other factors such as crowded unsanitary living conditions associated with low economic status, and exposure to cigarette smoke can increase the risk of being infected with RSV at a young age.
Respiratory Syncytial Virus
respiratory syncytial virus. Beers, M., Berkow, R. et al., 1999, Respiratory SyncytialVirus, in The Merck Manual, ed. Berkow, Merck Co., 13edition, p. 34.
http://www.bact.wisc.edu:81/ScienceEd/stories/storyReader$45

Extractions: Science articles that you can understand Posted by Timothy Paustian , 9/11/00 at 2:06:06 PM. by Lindsey Monk Sunday, August 6, 2000 Respiratory Syncytial Virus (RSV) is one of the most common viruses, yet most people who have been affected by the virus never realize they are ill. However, this particular virus can cause severe lower respiratory illnesses such as bronchiolitis and pneumonia in infants, young children and the elderly. This virus can also have serious physiological effects on distinct groups our population, especially children who were born premature or who have immunodeficiency's, chronic lung conditions or congenital heart disease. This particular virus is very dangerous to young children because of their undeveloped immune system. However, it is known that two types of RSV, Type A and Type B, exist. Type B causes a mild upper respiratory infection that affects almost everybody and Type A is a severe lower respiratory tract infection that mainly affects infants, the elderly and those with a compromised immune system. Pathophysiologically, RSV attacks the bronchoalveolar epithelium, causing epithelial cell necrosis and an inflammatory response with a peri-bronchiolar infiltrate of lymphocytes, plasma cells and macrophages (Miller et al.,1999). The feeble or those with weak or compromised immunes systems are susceptible to the most severe form of RSV. Infants and children are at high risk for lower respiratory tract infections caused by the Type A virus. According to Miller et al. (1999), RSV is responsible for 45% to 75% of all cases of bronchiolities and pneumonia in infants and young children. During a child's first RSV infection, between 25% and 40% of infants and young children have signs or symptoms of bronchiolitis or pneumonia (National Center for Infectious Disease). RSV also tends to occur between six-weeks and two years of life. The severe Type A virus tends to occur in very young children who have a history of prematurity, congenital heart disease, chronic lung conditions or immunodeficiency. Other factors such as crowded unsanitary living conditions associated with low economic status, and exposure to cigarette smoke can increase the risk of being infected with RSV at a young age.
Arch Pediatr Adolesc Med -- Page Not Found
156;10551056, October 2002, respiratory syncytial virus Infection and the Riskof Serious Bacterial Infections, Nathan Kuppermann, MD, MPH Kevin Purcell, MD
http://archpedi.ama-assn.org/issues/v156n10/ffull/plt1002-2.html

Extractions: The page you requested was not found. The JAMA Archives Journals Web site has been redesigned to provide you with improved layout, features, and functionality. The location of the page you requested may have changed. To find the page you requested, click here HOME CURRENT ISSUE PAST ISSUES ... HELP Error 404 - "Not Found"
Arch Pediatr Adolesc Med -- Page Not Found
Impact and Costeffectiveness of respiratory syncytial virus Prophylaxis for KansasMedicaid's High-Risk Children Author Information Theresa I. Shireman, PhD
http://archpedi.ama-assn.org/issues/v156n12/abs/poa10424.html

Extractions: The page you requested was not found. The JAMA Archives Journals Web site has been redesigned to provide you with improved layout, features, and functionality. The location of the page you requested may have changed. To find the page you requested, click here HOME CURRENT ISSUE PAST ISSUES ... HELP Error 404 - "Not Found"
RSV -- Respiratory Syncytial Virus
RSV respiratory syncytial virus. What is respiratory syncytial virus(RSV)? RSV What causes respiratory syncytial virus (RSV)? RSV
http://www.stlouischildrens.org/articles/kids_parents.asp?ID=2687
Respiratory Syncytial Virus (RS-virus)
RSvirus is short for respiratory syncytial virus which, in the wintermonths, is a common cause of acute bronchitis in small children.
http://www.netdoctor.co.uk/diseases/facts/rs.htm
Virtual Children's Hospital: CQQA: RSV (Respiratory Syncytial Virus)
RSV (respiratory syncytial virus). See related Patient Topics Lungs and Breathing,Respiratory DiseasesGeneral or respiratory syncytial virus Infections.
http://www.vh.org/pediatric/patient/pediatrics/cqqa/rsv.html
InteliHealth: Respiratory Syncytial Virus
format. respiratory syncytial virus. Health A to Z, Reviewed by theFaculty of Harvard Medical School respiratory syncytial virus
http://www.intelihealth.com/IH/ihtIH/WSIHW000/9339/23678.html
Respiratory Syncytial Virus (RSV) - Quick Facts
About respiratory syncytial virus (RSV). What is RSV? RSV is avirus that is spread from respiratory secretions through close
http://www.in.gov/isdh/healthinfo/rsv.htm

Extractions: for School Personnel: 2002 Health Care Professions Annual Reports 1997 Registered Nurse Survey 1997 Physicians Databook 1998 Dentist and Dental Hygienist Surveys ... Contact Us var dir = location.href.substring(0,location.href.lastIndexOf('www.in.gov/')); var url = location.href.substring(dir.length,location.href.length+1); document.write("") About ... Respiratory Syncytial Virus (RSV) What is RSV? RSV is a virus that is spread from respiratory secretions through close contact with infected persons or contact with contaminated surfaces or objects. How is RSV spread? RSV can occur when infectious materials contact eyes, mouth, and nose and possibly through the inhalation of droplets generated by a cough or sneeze. What are the symptoms of RSV? The symptoms of RSV are fever, runny nose, cough, and sometimes wheezing. How is RSV treated?
Respiratory Syncytial Virus
respiratory syncytial virus. induced pneumonic lesions. Contact geraldine.taylor.PUBLICATIONS (respiratory syncytial virus). Taylor G
http://www.iah.bbsrc.ac.uk/reports/1996/rsv.html
RESPIRATORY SYNCYTIAL VIRUS INFECTION
respiratory syncytial virus Infection.
http://www.iah.bbsrc.ac.uk/reports/1997/rsvi.html

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

21-40 of 95 Back | 1 | 2 | 3 | 4 | 5 | Next 20